cz en
CATRIN-IMTM

Laboratory of Experimental Medicine

The laboratory develops innovative therapeutics, biomarkers and diagnostic approaches for human diseases.
Research Areas
doc. MUDr. Marián Hajdúch, Ph.D.
Group leader
Phone +420585632127
E-mail marian.hajduch@upol.cz
Profile page

About the group

Research at the Laboratory of Experimental Medicine (LEM) focuses on human disease, development of innovative therapeutics, biomarkers and in vitro/in vivo diagnostics.  The main disease areas are cancer, rare diseases, inflammation and infectious diseases. LEM was established in 1998 at the Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc and eventually seeded the founding of IMTM in 2010. We are currently organized into five groups: Human Genetics; Imaging & Tracing; Molecular and Clinical Proteomics; Experimental Therapeutics and Bio/Chemoinformatics. The various groups complement each other and enable us to translate discoveries into clinical practice.

News

List of Employees

Name Academic title E-mail Phone Position
Marián Hajdúch doc. MUDr., Ph.D. marian.hajduch@upol.cz +420585632127 Group leader

Group publications

G. Gariglio, T. Hasenöhrl, K. Bendova, Z. Nový, C. Rangger, K. Kummer, B. D. Smith, B. Matuszczak, M. Petrik and C. Decristoforo
"Novel dimeric dual-modality FAP-targeted agents with favorable tumor retention for image-guided surgery: a preclinical study",
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 53, iss. 4, pp. 2578-2591, 2026.
IF = 7.6
CATRIN-IMTM
DOI: 10.1007/s00259-025-07626-z
V. Das and M. Hajdúch
"Oncology drug repurposing as a blueprint for Alzheimer's therapy",
ALZHEIMER'S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, vol. 12, iss. 1, article no. e70231, 2026.
IF = 7.4
CATRIN-IMTM
DOI: 10.1002/trc2.70231
M. Kraihammer, H. P. Varbanov, K. Dvořáková Bendová, M. Petřík, A. Yap, G. Gariglio, H. Haas and C. Decristoforo
"Repurposing carboplatin-based Pt(IV)-deferoxamine conjugates for infection theranostics",
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 301, pp. 118216, 2026.
IF = 6.7
CATRIN-IMTM
DOI: 10.1016/j.ejmech.2025.118216
D. Baručić, J. Stanková, J. Kybic, M. Hajdúch and P. Džubák
"Group-based learning on label-free phase-contrast images across dose and exposure time improves bioactive compound classification",
MACHINE LEARNING WITH APPLICATIONS, vol. 24, pp. 100867, 2026.
IF = 6.1
CATRIN-IMTM
DOI: 10.1016/j.mlwa.2026.100867
N. K. Rampeesa, R. Gundla, S. Gurská, S. Yadam, S. Tangallapalli, S. R. Anugu, J. B. De Sanctis, P. Džubák, M. Hajdúch, N. K. Katari, V. Das and S. B. Jonnalagadda
"Optimization of Azaspirooxindolinone-based PROTACs targeting BTK: Synthesis, kinase profiling, and degradation analysis",
RESULTS IN CHEMISTRY, vol. 23, pp. 103145, 2026.
IF = 5.8
CATRIN-IMTM
DOI: 10.1016/j.rechem.2026.103145
V. Das, S. M. Modarres Mousavi, N. Annadurai, S. Sukur, F. Mehrnejad, S. Moradi, L. Malina, M. Kolaříková, V. Ranc, I. Frydrych, R. Kouřil, S. Hosseinkhani, M. Hajdúch and M. Nikkhah
"Hydrophobic residues in the α‐synuclein NAC domain drive seed‐competent fibril formation and are targeted by peptide inhibitors",
THE FEBS JOURNAL, vol. 293, iss. 1, pp. 134-155, 2026.
IF = 4.2
CATRIN-IMTM
DOI: 10.1111/febs.70222
All group publications